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A B S T R A C T The possible interaction of Hageman factor from human or rabbit plasma with a variety of immunologic reactants was studied. Evidence of an interaction was not obtained and neither binding of radiolabeled Hageman factor to immune aggregates nor depletion of the Hageman factor from the supernate was observed. Cleavage of the labeled Hageman factor molecule into its 30,000 ;molecular weight-active fragments was not detectable after incubation with immune complexes.
Isolated Hageman factor was far more sensitive to activation than Hageman factor in plasma or serum. There was no consistent activation of isolated Hageman factor by immunologic reactants as determined by conversion of prekallikrein to its enzymatic form or by shortening of the clotting time of factor XII-deficient plasma. A variety of immunologic stimuli were tested: (a) antigen-antibody complexes in soluble or precipitated form; (b) particulate antigen-antibody complexes, i.e., zymosananti-zymosan in which a surface was presented for activation; (c) human IgM-IgG and IgG-IgG (rheumatoid factor) complexes; (d) immune aggregates consisting of heat or bis-diazotized benzidine-aggregated myeloma proteins of all human immunoglobulin classes and subclasses: IgGl,2,34, IgA, IgD, IgM, and IgE. Absorption with immune aggregates did not reduce the quantity of Hageman factor in solution, nor was the Hageman factor bound to the precipitates. The presence of plasma or serum with immune aggregates did not generate activity of the Hageman factor.
The only preparations of immunoglobulins capable of activating Hageman factor were found to be contami-
INTRODUCTION
Little is knowni about the participation of the kinin-forming and intrinsic clotting systems in inflammatory injury. Components of these systems may be activated by factors inducing inflammationi or by plasma and cellular participants brought into the site secondarily. Among the inciting factors capable of inducing inflammatory reactions that have been considered as activators of the kininforming and intrinsic clotting systems are complexes of antigen and antibodv.
Various mlethods have been employed to test for activationi of Hagemain factor and the kinin-forimiing system by immune reactants. Immune complexes have been added to fresh plasma to determine if kinin is released or kininogen depleted. Similarly, immune complexes have been added to normal plasma not previously exposed to glass to determine the effect upon the recalcification clotting time of the plasma. Finally, immune precipitates have been exposed to serum that had not contacted glass and the precipitates, after centrifugation, eluted to search for active components of the kinin system.
In order to measure activation of Hageman factor directly, it has been necessary to isolate and purify Hageman factor. In this way, the interaction with immune complexes could be measured directly and the effect upoIn the Hagemani factor molecule assessed. We have recently reported studies describing the purification and characterization of Hageman factor from human and rabbit plasma (1) . The molecule has been labeled with 'I for studies of its activation (2) . When negatively charged particles such as kaolin were added, the '"I-labeled Hageman factor became bound to the particles and was activated so as to generate the conversion of prekallikrein to kallikrein and to promote clotting of Hageman-deficient plasma. By contrast, when Hageman factor was exposed to an en-zyme such as trypsin, the molecule was cleaved into three equal-sized fragments of 30,000 daltons. These fragments, possessing enzymatic activity (3), were termed prekallikrein activator (PKA) .' In accordance with these findings, the activation of purified Hageman factor by immune reactants was assessed by (a) its ability to activate isolated prekallikrein or promote clotting of Hageman-deficient plasma; (b) its binding to immune reactants; and (c) its cleavage into 30,000 molecular weight subunits after interaction with immune reactants.
METHODS
Preparation of protein reagents. Hageman factor was prepared from human and rabbit plasma by methods recently described in this laboratory (1) . The Hageman factor was employed at a concentration of 50-100 ,g/ml. Briefly, plasma of each species was fractionated with ammonium sulfate. The fraction soluble at 25%o and insoluble at 55% saturation was then applied to a column of DEAE Sephadex A-50. After elution, the Hageman factor-rich fractions were passed successively over a second column of DEAE Sephadex A-50, G-200 Sephadex and CM Sephadex C-50. At no time did the plasma fractions touch glass. The Hageman factor thus obtained was free from apparent contaminating proteins as judged by electrophoresis in polyacrylamide gels. The Hageman factor did not contain functional activities of other members of the kinin-forming or intrinsic clotting systems (1) and contained undetectable quantities of plasminogen and plasmin. It would not activate prekallikrein or significantly promote clotting of factor XII-deficient plasma without prior activation with either kaolin or trypsin. This indicated the Hageman factor was in precursor form. The purified Hageman factor was labeled with 'I according to published methods (4) . After dialysis the 'I-labeled Hageman factor was passed over Sephadex G-75 to eliminate traces of free 'I. Evidence that the 'I label was bound to Hageman factor was as follows: the labeled protein eluted from G-200 Sephadex with the same volume of elution as unlabeled Hageman factor, sedimented at 4.5S in gradients of sucrose and, upon electrophoresis in polyacrylamide gel, migrated in the identical region where Hageman factor activity was detected.
Prekallikreini. Prekallikrein of rabbit plasma was prepared as published previously (5) . In general, prekallikrein that was passed over two columns of DEAE Sephadex A-50 was employed. This reagent (12.5 ,ug/ml) was stable, readily activated, and contained no detectable inhibitor of members of the kinin-forming system. Further purification on CM Sephadex C-50 and by electrophoresis in Pevikon (5) did not change the results.
Immunologic reactantts. Rabbit antibodies to human IgG (HGG), bovine IgG (BGG), and bovine albumin (BSA) were obtained after multiple injections of the proteins in saline. The antisera, containing 500-1000 ,ug antibody N/ml, were fractionated first with ammonium sulfate at 50% saturation, and then by DEAE-cellulose chromatography 1Abbreviations used in this paper: anti-BGG, rabbit antibody to bovine IgG; anti-BSA, rabbit antibody to bovine albumin; anti-HGG, rabbit antibody to human IgG; PKA, prekallikrein activator; TBS, tris-buffered saline; BAEe, benzoyl-l-arginine ethyl ester.
to obtain the 'y2-fraction. The quantity of antibody was measured by precipitin reaction. The pools of antibody were divided into portions and kept frozen. This was essential to avoid contamination with bacteria. To prepare immune complexes, antigen was added to the antibody at equivalence. After incubation at 37°C 30 min and at 4°C 30 min, the resulting precipitate was washed three times with cold 0.01 M Tris (hydroxymethyl) aminomethane pH 7.4 in 0.15 M NaCl (TBS). It was then resuspended in the same buffer and used for activation of Hageman factor. When tests were performed in an excess of antigen or antibody, or when the immune reactants were brought together in the presence of Hageman factor, the precipitation step was omitted. Zymosan was obtained from ICN Nutritional Biochemicals, Cleveland, Ohio. The zymosan was heated at 100°C 30 min and then washed. Antibodies were obtained by injecting rabbits with 5 mg zymosan in incomplete Freund's adj uvant at monthly intervals. The resulting antibody was fractionated as noted above for anti-HGG and labeled with 'I to allow quantitative measurements of the amount bound to zymosan.
Aggregationt of iinzmnziunoglobuilinis anid mnyeloma proteinis.
Myeloma proteins were isolated from the serum of patients with multiple myeloma either by DEAE-cellulose chromatography or Pevikon block electrophoresis. yA-and -yD-myeloma proteins were further purified by Sephadex G-200 gel filtration. The -yM-macroglobulins were isolated by euglobulin precipitation followed by gel filtration on Sephadex G-200 columns. The purified myeloma proteins and normal yG-immunoglobulin were then aggregated by heat at 63°C for 20 min or with bis-diazotized benzidine according to the method of Ishizaka, Ishizaka, Salmon, and Fudenberg (6).
Activation of Hagemant factor. Preparations of antibodies and antigens, aggregated myeloma proteins, and kaolin, etc., were added to Hageman factor. The Hageman factor employed was most frequently that in the peak tubes eluting from G-200 Sephadex, i.e., from the fourth step in purification. In the case of human Hageman factor, the concentration of Hageman factor in these tubes was 240-500 ,ug/ml as determined by quantitative immune diffusion assay. The Hageman factor was readily activated by 25 ,g kaolin or 1-2 ,ug trypsin. Volumes were brought to 0.15 or in some experiments 0.20 ml with TBS. Hageman factor was incubated with immune reactants for 20 min at either 37 or 2?0C. Prekallikrein, 1.2 ,ug or at times 3.5 gtg in 0.1 ml, was added and the incubation continued at 37°C 20 min. Following this, 3.0 ml 1 mm BAEe was added and the mixture incubated at 37°C for 30 min. Hydrolysis of BAEe was then measured by absorption of UV light at 253 nm (7) . The readings were corrected for the amount of absorption at 253 nm given by the protein present as measured at 280 nm. This was generally 70-90%o of the reading at 280 nm. The tubes were then warmed to 37°C for a second incubation of an additional 1 or 2 hr. The increase in absorption at 253 nm between the two periods was used as a measure of the degree of activation. Assays of clot promotion were performed by adding treated or control Hageman factor in 0.1-0.05 ml Hageman-deficient plasma in plastic tubes. After incubation for 6 min at 37°C, the tubes were brought to room temperature and 0.05 ml cephalin (Sigma Chemicals, St. Louis, Mo.) and 0.05 ml CaCl2, 0.05 M were added to the preparations. The interval in hundredths of minutes between addition of Ca++ and the time required for a solid clot to form at room temperature was recorded. Chromnatography anid iltracec trifulgationt were performed as published previously (1) .
Antibody to humnan Hageciian factor was prepared by immunizinig rabbits with Hageman factor obtained after four steps of purification, i.e, after fractionation by gel filtration oni G-200 Sephadex (1) . Anitibodies to contaminant proteins were removed by absorption wNith small quantities of Hageman-deficient plasma. The resulting antibody reacted with normal plasma to yield a single precipitin band in agar diffusion plates. No precipitate occurred with Hageman-deficient plasma from three individuals. The antibody reacted strongly with highly purified human Hageman factor obtained from clhromatography oni CM Sephadex C-50 (1).
Incutbationi of immtunte precipitates with serum or plasma. Assays of active componlen1ts of the kimin-formning system int elhiates of the precipitates. Rabbit anti-BGG, anti-HGG, and anti-BSA, 6 or 12 mg antibody protein were mixed with equivalent amounts of antigen in a plastic 40 ml tube, incubated at 37°C, 30 min, cooled to 4°C for 30 min, and centrifuged. The precipitates were washed three times in TBS, and mixed thoroughly with 10 ml fresh rabbit serum/ 6 mg antibody, or, in other experiments, guinea pig serum. The sera were obtained using siliconized needles and plastic containers. In two experiments, plasma obtained in acid citrate dextrose anticoagulant was substituted for serum. Incubation of precipitates and serum (or plasma) followed with agitation 10 min at 37°C. The precipitate was then removed by sedimentation, and treated with 5 ml of 0.5 M NaCl in 0.1 M Tris pH 8.0. The elution with 0.5 M NaCl was repeated twice, the first two eluates combined and dialyzed against an excess of TBS 18 hr. The dialyzed eluate was then assayed for its capacity to activate prekallikrein and reduce the clotting time of plasma. Plasma deficient in Hageman factor was generously contributed by Mrs. Gunda Hiatt and plasmas deficient in factors XI and IX by Dr. Samuel Rappaport. The precipitates, after elution, were washed with TBS. Control tubes included (a) immune precipitate with TBS instead of serum or plasma, (b) serum or plasma without immune precipitates (i.e., exposed only to the plastic tube), (c) serum or plasma mixed with 5 mg kaolin, and (d) precipitates exposed to serum that was washed once with 20 ml TBS before elution with 0.5 M NaCl. In some experiments, "2I-labeled Hageman factor was added to the serum or plasma to follow the molecule through various procedures.
RESULTS
Comparison of the capacity of sculipurificd anid nionipurified Hagemtan, factor to be activated. It was essential to determiine the comparative sensitivity of activation of Hageman factor in whole plasma and after isolation. Studies of the activation of Hageman factor should be performed on the most readily activated preparation. Accordingly, isolated human Hageman factor was obtained following the first four steps in purification, i.e., after elution from Sephadex G-200 (1). The tube conitaining the greatest concentration of Hageman factor and the least number of contaminating proteins was selecte(l. The Hageman factor so prepared was then tested for activation alone, or niixed with various concentrations of plasma obtained from an individual genetically tleficient in Hageman factor. In order to activate and absorb the Hageman factor. 125 iAg kaolin was added to each preparation in a constant final volume. After incubationi, the kaolin Nas sedimented, washed, and assayed for prekallikrein-activating (PKA) capacity. The stllernate was teste(d by quantitative immtlne diffusion for residual Hageman factor protein. The results are slhown in Table  I . They reveal that increasing concentrations of Hageman-deficient plasma interfere with the capacitv of Hageman factor to become bound to and activated by the kaolin. Similar inhibition of binding of 'I-labeled Hageman factor to kaolin by normal human plasma was observed in other experiments. The possib-ility was considered that inhibitors of PKA in plasma coul(d accouint Table V) .
In the subsequent studies, isolated Hageman factor was employed that was obtained from Sephadex G-200, i.e., the fourth step of purification. This course was preferable to that of the final step in purification (CM Sephadex C-50) because of greater concentrations of the Hageman factor and because of a lessened tendency to activate spontaneously.
Tests for activation of isolkted Hageman factor by immitune precipitates. Immune precipitates consisting of rabbit antibodies to BSA, BGG, and HGG and their respective antigens were prepared at equivalence. After washing in TBS they were exposed to rabbit Hageman factor and assays were performed of possible activation. Little (Table III) .
In order to find if fresh serumi was important in the activation of Hageman factor, fresh normal rabbit or Figs. 3 and 4 . As noted, the immune complexes or rheumatoid factor-aggregated IgG complexes sedimented more rapidly than the 'I-labeled Hageman factor. The pattern of Hageman factor in the presence of immune complexes was indistinguishable from that in the absence of immune complexes. In addition, no evidence of breakdown of Hageman factor into its 2.6S subunits was observed. The addition of fresh rabbit plasma or human serum to the incubation mixture (diluted one-fifth in the protein solutions) did not alter the pattern of sedimentation of the Hageman factor. It should be emphasized that the 'I-labeled Hageman factor was fully capable of binding to and being activated by kaolin. When tested before sedimentation, the Hageman factor was found not to be activated by the immune complexes.
Attempts to elute active produtcts of Hageman factor from immuine precipitates exposed to normal plasma or serum. Precipitates of rabbit anti-BSA, BGG, and HGG were prepared with equivalent amounts of antigen, exposed to fresh serum or plasma, and eluted with 0.5 M NaCl as described in Methods. The eluates were dialyzed and tested in various quantities for their ability to activate prekallikrein and promote clotting of plasma. Five experiments were performed, yielding similar data.
The results of one such experiment are shown in Table IV . As noted, active Hageman factor did not appear in the eluate as tested by prekallikrein activation, while eluates of kaolin treated with normal serum These studies were facilitated by the availability of MI-labeled human and rabbit Hageman factor and by antibodies directed to the former. These reagents allowed quantitative measurements to be performed on the amount of Hageman factor participating in reactions whether or not it was activated. This is especially important in the present studies in which activation by immune complexes was not observed. All of the Hageman factor could be accounted for at the end of the reaction, which substantiated considerably the results.
In addition, it was determined at the outset of these experiments that Hageman factor was far more readily activated after partial purification. Thus, the ability to detect activation was particularly sensitive.
The present studies are in keeping with those of Ratnoff (9) and Robbins and Stetson (10) (18) . In addition, elution of unwashed precipitates followed by chromatographic analysis allowed identification of several factors capable of activating members of the kinin system (18, 19) . However, it is quite possible that activation of the eluates obtained fronm immune precipitates resulted from the process of dialvsis and chromatography. In fact, this has been shown to occur when proper precautions are not taken (3, 5, 20) . In the present studies, abundant Hageman factor, i.e. about 12-15% of that added in normal serum, remained in the plastic tubes after serum iwas decantedI from the immune precipitates. One-half of this was bound to the tube and essentially all of the remainder could be washed from the precipitate with physiologic saline. The Hageman factor bound to the plastic tube and that removed from precipitate by washing was inactive. Thus elution of the serum treated, unwashed immune precipitate with high concentrations of NaCl (18) rheumatoid factor activity reacted with IgG to release kinin from plasma that contracted rat uterus and depleted levels of kininogen. The amount of kinin released paralleled the titer of rheumatoid factor. It should be noted that these investigators employed chelated plasma which did not support generation of the vascular permeability factor studied by MIovat and DiLorenzo (15) . The two factors are therefore probably different. Hageman-deficient plasma failed to support generation of the kinin. In the present studies, isolated Hageman factor was neither bound to nor activated by rheumatoid factor-aggregated IgG complexes. Addition of serum or plasma had no effect oIn the results. In addition, rheumatoi(I factor of high titer (1,000-10,000 reciprocal dilution) isolated chromatographically. was combined with heat-aggregated IgG. This was then added to plasma pretreated with 1-10-orthophenanthroline under conditions identical with those of Epstein et al. (23) . Nevertheless, with seven different preparations of rheumatoid factor we failed to obtain either specific kinin release or kininogen depletion. Addition of 200 Ag kaolin/nml plasma in the presence of each rheumatoid factor and heat-aggregated IgG generated kinin and depleted kininogen levels up to 40%ff6. The reason for this discrepancy is not apparent.
Actiz'ation by bactcria. In the only instances in wvhich aggregated immunoglobulins, immune complexes, or isolated rheumatoid factors were capable of generating activity fronm the precursor Hageman factor, bacterial contamination wvas found in the preparation of imimiuinoglobulin. The bacteria, upon culture and isolation, were capable of activating the Hageman factor. In two cases, Pscudomona.s alcaligenes and in a third, E. coli were identified. This finding may illustrate a mechanism of activation of the kinin-forming and intrinsic clotting systems of considerable importance in the host's defense against invading organisms. In addition, it represents a pitfall to investigations of the activationi of the kinin-forming system than can mislead proper interpretation.
